ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate
(tenofovir DF) is the first complete HAART that is offered as one tablet once a day. The
individual components of this HAART regimen have demonstrated efficacy and safety in HIV
treatment-naive patients and offer simplification that in turn may increase adherence and
improve clinical outcomes. This study aims to evaluate the effectiveness (efficacy, safety
and tolerability) of a STR simplification strategy in patients on HAART who have achieved
viral suppression in a real world clinical setting.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination